Recently Launched Products Support Novartis AG Sales in Third Quarter, Offsetting Patent Expiry; Pharmaceuticals Well-Positioned With Further Pipeline Progress

Published: Oct 25, 2012

BASEL, Switzerland--(BUSINESS WIRE)--Regulatory News:

Novartis (SIX: NOVN) (NYSE:NVS):

Core results and free cash flow are non-IFRS measures. An explanation of these non-IFRS measures and reconciliation tables can be found beginning on page 44 of the Interim Financial Report, together with the additional data listed in the index below. These are available on our website at http://www.novartis.com/investors/financial-results/quarterly-results-q3-2012.shtml.

Back to news